Endocrine Abstracts

Abstract unavailable....

The gut hormone glucagon-like peptide (GLP)-1 lowers blood glucose by stimulating meal-related insulin secretion and lowering hyperglucagonaemia in a glucose-dependent manner. Currently, injectable GLP-1 receptor agonists (GLP-1RA) and oral inhibitors of the dipeptidyl peptidase (DPP)-4 enzyme, that degrades native GLP-1, are successfully employed in the treatment of type 2 diabetes (T2DM). Clinically relevant extrapancreatic effects of GLP-1 (RA) involve slowing down gastric ...

Glucagon-like peptide 1 (GLP-1) is a gut hormone that broadly promotes glucose homeostasis through the regulation of islet hormone secretion. Interestingly, GLP-1 has been reported to be both cause and cure of type 2 diabetes mellitus (T2DM). Decreased GLP-1 is thought to cause the progression from impaired glucose tolerance to frank T2DM. Conversely, the GLP-1 system has been successfully targeted as a treatment option for T2DM patients and increases in GLP-1 have been implic...